PRP/Cell-Based/Osteoinductive Materials

Orthobiologics Face Pressure from Lack of Clinical Evidence

Orthobiologics Face Pressure from Lack of Clinical Evidence
In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence.

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface

Anika Therapeutics Takes Major Step in Strategic Transformation with Acquisition of Parcus Medical and Arthrosurface
With the acquisitions of Parcus Medical and Arthrosurface, Anika looks ready to complete a major step in its five-year strategic plan to become a leader in joint preservation and restoration.

Member-Only Content

SUBSCRIBE Login

Royal Biologics Gains Funding

Royal Biologics, developer of products for regenerative medicine, received funding to support employee onboarding, operational growth, product development and acquisitions. 

Bone Therapeutics to End Phase III PREOB Study

The Data and Safety Monitoring Board recommended discontinuation of the Phase III hip osteonecrosis study of Bone Therapeutics' PREOB viscosupplement, following interim analysis of results.

Stryker Posts 2Q18 Revenue Growth of 8% YoY

ORTHOWORLD estimates Stryker's 2Q18 orthopaedic revenue at US $1,747.8MM, +8.0% from 2Q17, and 1H18 revenue at $3,472.6MM, +7.5% vs. 1H17. Trauma and Extremities Joint Recon remain high performers, with Interventional and Tritanium products contributing to strong spine segment growth.

Member-Only Content

SUBSCRIBE Login

DiscGenics Raises $14 Million for Injectable Cell Therapy

DiscGenics closed a US $14MM Series B financing. Funds will support regulatory approvals and manufacturing ramp-up for Phase III clinical and commercial production of its cell therapy for treatment of degenerative disc disease.

Three-Month Interim Safety Data from Phase I Clinical Trial of AlloJoin

Three-month safety data from a Phase I clinical trial in China for Cellular Biomedicine's AlloJoin™ off-the-shelf allogeneic stem cell therapy in the treatment of knee osteoarthritis demonstrated a safety and tolerability profile of AlloJoin in the three doses tested, with adverse events similar to that of earlier autologous trials. The trial is slated for completion in 3Q17.

OSTEOGROW Research Update

OSTEOGROW, an EU-funded collaborative research project, is investigating a new bone regeneration therapy based on autologous blood + BMP-6 for use in applications requiring partial bone replacement, without the need for secondary interventions. 

MiMedx to Acquire Stability Biologics

MiMedx signed a definitive agreement to acquire Stability Biologics for US $10MM in cash and stock. Stability Biologics provides human tissue products for the surgical, spine and orthopaedic industries. The transaction is expected to close in early 1Q16.

Bone Therapeutics Granted Additional EUR 2MM in Funding

Bone Therapeutics was granted an additional 2MM (~US $2.15MM) in non-dilutive funding, bringing the total non-dilutive funding received within 2015 to 5MM.